Asthma + Lung UK’s Post

Today is #worldbronchiectasisday a condition that is still poorly understood with no approved therapies. Recent data from EMBARC, the largest series of people with bronchiectais worldwide, highlighted that airway clearance is prescribed primarily on the basis of geographical location, not evidence. This is a huge burden to put on families. Insmed Incorporated’s brenscotanib maybe closer to approval but there is still much to understand about the respiratory microbiome and the role of potential modulators. Cystic fibrosis and primary ciliary dyskinesia are both neutrophilic endotypes of bronchiectasis. While CF has modulators that address 90% of the population, PCD has worse outcomes in children, an inequitable standard of care and no approved therapies. Both populations could be combined to better understand antimicrobilal resistance. #bronchiectasis #bronchiectasisneedsmore #primaryciliarydyskinesia

As Scientific Director at CoRE, a new clinic at Mount Sinai in NYC, PolyBio President Dr. Amy Proal designs and implements clinical trials for Infection-Associated Complex Chronic Condition (#IACC) patients. Along with David Putrino, she’s investigating repurposed HIV-antivirals Truvada & Maraviroc as potential Long COVID treatments and the fibrinolytic enzyme Lumbrokinase to treat Long COVID, ME/CFS and Lyme+. She speaks regularly with the CoRE scientific team on key issues surrounding complex chronic illness. This video series is a part of an ongoing effort at CoRE to educate patients on the mechanisms of their chronic conditions. You can access these free seminars here 👇🏻: https://lnkd.in/e6EXrD6c #longcovid #infectionassociatedchronicillness #mecfs #lyme+

Bruce Ellsworth, PhD, and Aryeh Fischer, MD, discuss drug discovery and potential new advances in treating #PulmonaryFibrosis in this Q&A. We understand the challenges faced by individuals living with pulmonary fibrosis, as breathlessness can greatly impact their daily lives. That's why we remain committed to pursuing pathbreaking science that may help patients in need. Read the full article here: https://bit.ly/3ywHlFS #ATS2024

Game changing advance in healthcare for one of the most common and dreaded complications: Sepsis. Follow us to learn more about research and innovation at St. Michael’s.

Cardiovascular disease is the leading cause of death for women worldwide,¹ yet women are still under-referred and undertreated for aortic valve replacement.²,³ Learn how the Medtronic #SMARTtrial is combatting underrepresentation in clinical research and making a difference for women with #AorticStenosis - https://bit.ly/4atf9SF #HealthEquity #TAVR Risk Info: https://bit.ly/43UG9b6 1. Vogel B, et al. Lancet. 2021 ;397 :2385-2438. 2. Erin Blakemore. Women are still underrepresented in clinical trials. Published June 27, 2022. Accessed on March 25, 2024. 3. L.A. McKeown. Stark inequities plague AVR rates for women, minorities in England. Published October 4, 2023. Accessed on March 25, 2023.

Last week, our group member Tonje R. Johannessen kicked off the study OUT-POC (One-hoUr Troponin using a high-sensitivity Point-Of-Care assay in emergency primary care) at the Emergency Room in Oslo! 🚀 This pilot study aims to evaluate the efficacy of high-sensitivity #troponin testing in an emergency room setting, with the goal of enhancing chest pain diagnostic🫀 Universitetet i Oslo Oslo University Hospital Oslo Center for Clinical Heart Research Sigrun Halvorsen Dan Atar Oslo Kommune Velferdsetaten Helseetaten, Oslo kommune #EmergencyMedicine #CardiologyResearch #HealthcareInnovation

Cardiovascular disease is the leading cause of death for women worldwide,¹ yet women are still under-referred and undertreated for aortic valve replacement.²,³ Learn how the Medtronic #SMARTtrial is combatting underrepresentation in clinical research and making a difference for women with #AorticStenosis - https://bit.ly/4bdNDJ2 #HealthEquity #TAVR Risk Info: https://bit.ly/4bnMgry 1. Vogel B, et al. Lancet. 2021;397:2385-2438. 2. Blakemore E. Women are still underrepresented in clinical trials. Published June 27, 2022. Accessed on March 25, 2024. 3. McKeown LA. Stark inequities plague AVR rates for women, minorities in England. Published October 4, 2023. Accessed on March 25, 2023.

TUN Conference 2024 completed ✔️. Great topics discussed including Sacral Neuromodulation; ANP led Remote Kidney Monitoring; and the launch of our Barriers to home therapies and FLARE projects; and of course ‘the patient journey’ 👏🏼👏🏼

Top liver specialists are embracing HEPAVu® for its cutting-edge technology and intuitive workflow. With groundbreaking tools like SWE for liver fibrosis assessment and Q-Liver PL.U.S for steatosis evaluation, it’s making liver diagnostics faster and more reliable. Sandeep Wadhwa | Hari S. Kaimal | Sanju Nair | Massimo Rosa | Jean-Pierre Henry | Soufiane Ouhda #LiverDiagnostics #HepaVu #MedicalDevices #LiverHealth